

REMARKS

Claims 1-12, 14 and 16-33 are pending in the present application.


The specification has been amended to reflect the status of the application as a national phase application and to set forth foreign priority.

Claims 13 and 15 have been canceled without prejudice or disclaimer thereto. Claims 17-33 are newly added. Various claims as indicated above have been amended to address multiple dependencies and better place the subject matter in condition for U.S. examination. None of the amendments are made in view of the prior art.

Entry of the amendment prior to the calculation of the filing fee and examination of the application is respectfully requested.

Respectfully submitted,

Date: January 25, 2005



Robert J. Smith  
Reg. No. 40,820  
Attorney for Applicants

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, NC 27709-3398  
Direct Phone (919)483-9616  
Facsimile (919)483-7988